In this study, 2 albumin binder–conjugated FAPIs, denoted as TEFAPI-06 and TEFAPI-07, were developed to optimize the pharmacokinetics of current FAPI radiopharmaceuticals for cancer radiotherapy. This evidence concerns the gene ALB and cancer.